EGFR anticorps (pTyr845) (Alexa Fluor 647)

N° du produit ABIN1177050

Détail du produit anti-EGFR anticorps (Alexa Fluor 647)

Antigène: EGFR (Epidermal Growth Factor Receptor (EGFR))

Épitope: pTyr845

Reactivité: Humain, Souris, Rat

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp EGFR est conjugé à/à la Alexa Fluor 647

Application: Intracellular Staining (ICS)

Marque: BD Phosflow™

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogène: Phosphorylated Human EGF Receptor Peptide

Clone: 12A3

Isotype: IgG1 kappa

Information d'application

Volume d'échantillon: 20 μL

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Aqueous buffered solution containing BSA and ≤0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The antibody was conjugated to Alexa Fluor® 647 under optimum conditions, and unreacted Alexa Fluor® 647 was removed.

Références pour anticorps anti-EGFR (Alexa Fluor 647) (ABIN1177050)

Mendelsohn, Baselga: "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer." dans: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 21, Issue 14, pp. 2787-99, (2003) (PubMed).

Détails sur EGFR

Antigène: EGFR (Epidermal Growth Factor Receptor (EGFR))

Autre désignation: EGF Receptor (EGFR Produits)

Synonymes: anticorps C-erb, anticorps CG10079, anticorps D-EGFR, anticorps D-Egf, anticorps DEGFR, anticorps DER, anticorps DER flb, anticorps DER/EGFR, anticorps DER/faint little ball, anticorps DER/top, anticorps DER/torpedo, anticorps DER1, anticorps DEgfr, anticorps Degfr, anticorps Der, anticorps DmHD-33, anticorps Dmel\\CG10079, anticorps EFG-R, anticorps EGF-R, anticorps EGFR, anticorps EGFr, anticorps EGfr, anticorps EK2-6, anticorps Egf, anticorps Egf-r, anticorps EgfR, anticorps El, anticorps Elp, anticorps Elp-1, anticorps Elp-B1, anticorps Elp-B1RB1, anticorps HD-33, anticorps TOP, anticorps Torpedo/DER, anticorps Torpedo/Egfr, anticorps c-erbB, anticorps d-egf-r, anticorps dEGFR, anticorps dEGFR1, anticorps dEgfr, anticorps der, anticorps egfr, anticorps flb, anticorps l(2)05351, anticorps l(2)09261, anticorps l(2)57DEFa, anticorps l(2)57EFa, anticorps l(2)57Ea, anticorps mor1, anticorps top, anticorps top/DER, anticorps top/flb, anticorps torpedo/Egfr, anticorps torpedo/egfr, anticorps EGFR12, anticorps EGFR15, anticorps egfr1, anticorps Erbb2, anticorps ERBB, anticorps ERBB1, anticorps HER1, anticorps PIG61, anticorps mENA, anticorps ErbB-1, anticorps Errp, anticorps 9030024J15Rik, anticorps AI552599, anticorps Erbb, anticorps Errb1, anticorps Wa5, anticorps wa-2, anticorps wa2, anticorps epidermal growth factor receptor, anticorps Epidermal growth factor receptor, anticorps epidermal growth factor receptor a (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian), anticorps EGFR, anticorps Egfr, anticorps egfra, anticorps egfr1, anticorps LOC5564544

Sujet: Epidermal Growth Factor (EGF) elicits a variety of cellular responses that are initiated by EGF Receptor (EGFR) binding and activation of intrinsic tyrosine kinase activity. EGFR, also known as ErbB1 or HER1, is a member of the ErbB class of receptor protein tyrosine kinases. It has an extracellular ligand-binding domain, a single transmembrane region, and a cytoplasmic region containing a protein tyrosine kinase domain and a c-terminal regulatory domain with many phosphorylation sites. Following ligand binding, EGFR forms homodimers and heterodimers with ErbB2. Specific C-terminal tyrosine residues are then autophosphorylated and, in turn, bind to adaptor proteins, kinases, or protein tyrosine phosphatases. In addition, c-Src-dependent phosphorylations at other sites, such as tyrosine 845 (Y845) in the kinase domain, regulate the receptor's kinase activity. Inappropriate expression or mutations of EGFR and/or deregulation of its signaling pathways are associated with many types of cancer, making EGFR a promising target for cancer therapies. The 12A3 monoclonal antibody recognizes the phosphorylated Y845 in the protein tyrosine kinase domain of human EGFR.

Pathways: Signalisation NF-kappaB, Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation, S100 Proteins